A case of a life-threatening toxicity following capecitabine treatment: advocacy for dihydropyrimidine dehydrogenase deficiency screening

Houssiau, Hélène;Duck, Lionel;Carlier, Séverine;Poncin, Renaud;Haufroid, Vincent;et.al.
(2020) Belgian Journal of Medical Oncology — Vol. 14, n° 4, p. 150-153 (2020)

Files

2020_Houssiau_Belg_J_Med_Oncol.pdf
  • Open Access
  • Adobe PDF
  • 100.35 KB
Download

Details

Authors
Show more
Abstract
We discuss a life-threatening case of capecitabine toxicity due to the presence of a heterozygous variant on exon 14 (c.1905+1G>A, rs3918290) of the dihydropyrimidine dehydrogenase gene (DPYD). We advocate the need for dihydropyrimidine dehydrogenase deficit screening, which could become mandatory in Belgium, as in France, before any fluoropyrimidine administration to avoid cases of foreseeable toxicity.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Houssiau, H., Duck, L., Carlier, S., Poncin, R., Whenham, N., & Haufroid, V. (2020). A case of a life-threatening toxicity following capecitabine treatment: advocacy for dihydropyrimidine dehydrogenase deficiency screening. Belgian Journal of Medical Oncology, 14(4), 150-153. https://hdl.handle.net/2078.5/118316 (Original work published 2020)